Literature DB >> 25789911

Assessing the methodological quality of systematic reviews.

Emma J Welsh1, Rebecca A Normansell1, Christopher J Cates1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25789911      PMCID: PMC4373473          DOI: 10.1038/npjpcrm.2015.19

Source DB:  PubMed          Journal:  NPJ Prim Care Respir Med        ISSN: 2055-1010            Impact factor:   2.871


× No keyword cloud information.
Dear Sirs, We read with interest the paper by Ho et al,[1] which used the AMSTAR tool to assess the methodological quality of systematic reviews (SRs) on chronic obstructive pulmonary disease (COPD). As staff at the Cochrane Airways Group with the responsibility of producing high-quality SRs for airway conditions, including COPD, we are always happy to hear how we could improve. However, there are some methodological issues within the study. The abstract states that the methodological quality of the reviews was disappointing and emphasises the more negative findings, neglecting the positive results (e.g., a priori design in 67% SRs, comprehensive literature search in 97% and scientific quality assessed and documented in 85%). The authors did not complete the AMSTAR ratings in duplicate; yet, duplicate data extraction is a mark of a good SR. Our experience with this tool is that the discussion between two or more people helps reach a fair judgement.[2] It would have been helpful to see the AMSTAR ratings per review so that the work could be replicated and evaluated. We noted the lack of discussion about the choice to limit the study to SRs that include a meta-analysis. Choosing not to perform a meta-analysis when there is a lot of heterogeneity between studies is a valid decision. The authors highlighted that non-English databases were searched infrequently. This is not an AMSTAR criterion; have the authors suggested that this be incorporated in any update of the tool? Cochrane does not require that non-English language databases be searched and this is usually done only when we expect that this will yield additional relevant trials. We agree that multilingual SR teams are advantageous and we would be grateful if people who wish to translate the trial reports for inclusion in Cochrane reviews contact us. We take the authors’ point about being clearer about reviewers’ support, and making a statement about publication bias in the results section as well as the methods section when there are too few studies to permit a funnel plot. As highlighted in the paper, the quality of SRs has improved significantly in recent years through the development of methods and improved implementation.[3,4] It would have been helpful to highlight this important point in the conclusions and abstract.
  2 in total

Review 1.  Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews.

Authors:  Christopher J Cates; Marta Oleszczuk; Elizabeth Stovold; L Susan Wieland
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

2.  Methodological quality of meta-analyses on treatments for chronic obstructive pulmonary disease: a cross-sectional study using the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) tool.

Authors:  Robin S T Ho; Xinyin Wu; Jinqiu Yuan; Siya Liu; Xin Lai; Samuel Y S Wong; Vincent C H Chung
Journal:  NPJ Prim Care Respir Med       Date:  2015-01-08       Impact factor: 2.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.